Literature DB >> 24007628

Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients.

Audrey Vallée1, Marie Marcq, Acya Bizieux, Claude El Kouri, Hervé Lacroix, Jaafar Bennouna, Jean-Yves Douillard, Marc G Denis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24007628     DOI： 10.1016/j.lungcan.2013.08.014

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  21 in total

Review 1.  Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Authors:  Abhijit Pal; Rajiv Shinde; Manuel Selvi Miralles; Paul Workman; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2021-03-24       Impact factor: 66.675

2.  Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma.

Authors:  Liqiang Xi; Trinh Hoc-Tran Pham; Eden C Payabyab; Richard M Sherry; Steven A Rosenberg; Mark Raffeld
Journal:  Clin Cancer Res       Date:  2016-08-01       Impact factor: 12.531

3.  Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.

Authors:  Huanli Duan; Junliang Lu; Tao Lu; Jie Gao; Jing Zhang; Yan Xu; Mengzhao Wang; Huanwen Wu; Zhiyong Liang; Tonghua Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study.

Authors:  Marc G Denis; Marie-Pierre Lafourcade; Gwenaëlle Le Garff; Charles Dayen; Lionel Falchero; Pascal Thomas; Chrystèle Locher; Gérard Oliviero; Muriel Licour; Martin Reck; Nicola Normanno; Olivier Molinier
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

Review 5.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

Authors:  Marius Ilie; Véronique Hofman; Elodie Long; Olivier Bordone; Eric Selva; Kevin Washetine; Charles Hugo Marquette; Paul Hofman
Journal:  Ann Transl Med       Date:  2014-11

6.  EGFR Mutation Analysis in Non-small Cell Lung Carcinoma Patients: A Liquid Biopsy Approach.

Authors:  Jigna Joshi; Apexa Raval; Urja Desai; Vinal Upadhyay; Mansi Bhavsar; Kanisha Shah; Rakesh Rawal; Harsha Panchal; Franky Shah
Journal:  Indian J Clin Biochem       Date:  2019-12-04

7.  Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?

Authors:  Marie Marcq; Audrey Vallée; Acya Bizieux; Marc G Denis
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

8.  Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).

Authors:  James L Sherwood; Claire Corcoran; Helen Brown; Alan D Sharpe; Milena Musilova; Alexander Kohlmann
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

Review 9.  Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring.

Authors:  Yi Chang; Bhairavi Tolani; Xiuhong Nie; Xiuyi Zhi; Mu Hu; Biao He
Journal:  Ther Clin Risk Manag       Date:  2017-10-11       Impact factor: 2.423

10.  Snapback primer mediated clamping PCR for detection of EGFR and KRAS mutations in NSCLC patients by high resolution melting analysis.

Authors:  Haiyan Sun; Yang Yang; Lixin Yang; Bo Su; Gening Jiang; Ke Fei; Daru Lu
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.